期刊文献+

MAGE-3 DNA疫苗的构建及其免疫效果的观察 被引量:6

Construction of Human MAGE-3 DNA Vaccine and Its Immune Effects Observed in vivo
在线阅读 下载PDF
导出
摘要 通过RT PCR方法扩增MAGE 3cDNA ,以pcDNA3 1+为载体 ,构建重组表达质粒pcDNA3 1 MAGE 3。重组质粒用脂质体转染鼠B16细胞 ,经RT PCR、细胞免疫染色及免疫印迹法鉴定转化细胞中MAGE 3的表达。以 10 0 μg质粒剂量肌肉注射接种小鼠 ,间隔 10天 ,共 3次 ,以空载体和PBS为对照。结果 ,重组质粒免疫的小鼠 ,其脾淋巴细胞对MAGE 3阳性靶细胞的杀伤活性为 51 0 8± 7 41% ,与空载体组 (8 44± 1 89% )及PBS组 (5 76± 1 75% )相比 ,差异有显著性 (P <0 0 1) ,而对MAGE 3阴性靶细胞的杀伤活性分别为 8 2 1± 1 65% ,7 68± 1 56%和 5 13±1 42 % ,其差异无显著性 ;MAGE 3DNA疫苗组免疫血清 1∶15稀释时能检测到抗MAGE 3抗体 ,脾细胞培养上清中Th1类细胞因子IFN γ、IL 2水平明显升高 ,外周血中CD4+、CD8+T细胞也提高 ,小鼠肿瘤的生长速度明显减慢 ,与对照组相比 ,差异显著 (P <0 0 1)。说明MAGE To investigate the antitumor immune responses induced by MAGE-3 DNA vaccine, th e recombinant mammalian expression plasmid pcDNA3 1/MAGE-3 was constructed by ligating MAGE-3 gene, which was amplified by RT-PCR, and the pcDNA3 1+ vector . The recombinant plasmids were transfected into B16 cells by liposome, the expr ession of MAGE-3 was checked by RT-PCR, immunocytochemistry and Western blot . Then, 100ug recombinant plasmids were injected intramuscularly per C57BL/6 mou se on 0, 10 and 20 days, with pcDNA3 1+ plasmid and PBS as controls. Splenocyte s CTLs、 the level of antibodies against MAGE-3、the changes of the T lymphocyt e subsets and the levels of cytokines were checked after 3 times immunization. As a result, the mice immunized with pcDNA3 1/MAGE-3 plasmid can produce MAGE -3 specific immune response. The CTLs kill activities against B16/MAGE-3 cells was 51 08±7 41%, and had significant difference(P<0 01) compared with t hat of pcDNA3 1+ group(8 44±1 89%) and PBS group(5 76±1 75%). The titre of an tibody against MAGE-3 was 1∶15, while controls were negtive. The number of CD 4+、CD8+ and the levels of IFN-γ、IL-2 increased significantly after immuniz ation with pcDNA3 1/MAGE-3 plasmid as compared with those of control groups( P<0 01). It is concluded that the pcDNA3 1-MAGE-3 DNA vaccine are able to i nduce both cellular and humoral immune responses in vivo.
出处 《生物工程学报》 CAS CSCD 北大核心 2004年第2期165-169,共5页 Chinese Journal of Biotechnology
关键词 MAGE-3 DNA疫苗 免疫应答 脂质体 重组质粒 肿瘤 真核表达 MAGE-3, RT-PCR, clone, mammalian expression,DNA vaccine,immune response
  • 相关文献

参考文献1

二级参考文献14

  • 1[1]Lucas S, De Smet C, Ardem K C et al. Identification of a new MAGE gene with tumor-specific expression by representational difference analysis. Cancer Res, 1998, 58(4): 743-752
  • 2[2]Tahara K, Mori M, Sadanaga N et al.Expression of the MAGE gene family in human hepatocellular carcinoma. Cancer, 1999, 85(6): 1234-1240
  • 3[3]Chen C H, Huang G T, Lee H S et al. High frequency of expression ofMAGE genes in human hepatocellular. Liver, 1999, 19(2):110-114
  • 4[4]Melief C J, Toes R E, Medema J P et al. Strategies for immunotherapy of cancer. AdvImmunol, 2000, 75: 235-282
  • 5[5]Chaux P, Vantomme V, Stroobant V et al. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4+ T lymphocytes. J Exp Med, 1999, 189(5): 767-777
  • 6[6]Manici S, Sturniolo T,Imro M A et al. Melanoma cells present a MAGE-3 epitope to CD4+ cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J Exp Med, 1999, 189(5): 871-876
  • 7[7]Miconnet I, Servis C, Cerottini J C et al. Amino acid identity and/or position determines the proteasomal cleavage of the HLA-A 0201-restricted peptide tumor antigen MAGE-3 271-279. J Bio Chem, 2000, 275(35): 26892-26897
  • 8[8]Eifuku R, TakenoyamaM, Yoshino I et al. Analysis of MAGE-3 drived synthetic peptide as a human lung cancer antigen recognized by cytotoxic T lymphocytes. Int J Clin Oncol, 2001, 6(1): 34-39
  • 9[9]Toungouz M, Lambermont M, Velu T et al. Anti-tumor immunotherapy based ondendritic cells. J Soc Biol, 2001, 195(1):19-23
  • 10[10]Weber J S, Hua F L, Spears L et al. A phase I trial ofan HLA-A1 restricted MAGE-3 epitope peptide with incomplete freunds adjuvant in patients with resected high-risk melanoma. J Immunother, 1999, 22(5): 431-340

共引文献2

同被引文献55

引证文献6

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部